Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

GlobeNewswire

May 06, 2024



Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found...

Related Keywords

Germany ,Ingelheim ,Rheinland Pfalz ,Quan Dong Nguyen ,Ulrike Graefe Mody ,Animal Health ,Head Of Retinal Health At Boehringer Ingelheim ,Pediatrics At Stanford School Of Medicine ,Byers Eye Institute ,Association For Research ,Boehringer Ingelheim ,Stanford School ,Coordinating Investigator ,Retinal Health ,Human Pharma ,Corporate Headquarters ,Ophthalmol Vis Sci ,